[Application of NFkappaB inhibitor for arthritis].
Recent progress in DNA technologies has provided the strategies to regulate the transcription of disease-related genes in vivo using antisense oligodeoxynucleotide (ODN). Transfection of cis-element double-stranded oligodeoxynucleotides (decoy ODNs) has been reported as a new therapeutic tool of anti-gene strategies for gene therapy. In the field of arthritis, decoy ODNs strategies have been significant therapeutic potential. The concept of regulation the disease related gene expression at the level of transcriptional factor may be more therapeutic effects compared with monotherapy in arthritis. Injection of NFkappaB decoy ODN into the affected joint resulted in marked suppression of joint destruction in CIA models. In vitro studies demonstrated that the inhibitory effect on inflammatory cytokines and matrix metalloproteinase production from stimulated synovial cells derived from rheumatoid arthritis patients. NFkappaB decoy ODN inhibited induction of osteoclasts and bone resorption ability. Parthenolide is one of the main sesquiterpense lactones responsible for the bioactivities of feverfew and recently reported to inhibit NFkappaB activation. Parthenolide has ameliorated the severity of joint destruction in experimental animal model. Based upon these findings, NFkappaB may be one of important therapeutic target for arthritis.
Tomita
Tetsuya
T
Department of Orthopaedics, Osaka University Graduate School of Medicine.
Kunugiza
Yasuo
Y
Nomura
Koji
K
Morimoto
Daiki
D
Kuroda
Shoko
S
Yoshikawa
Hideki
H
D000818:Animals; D001172:Arthritis, Rheumatoid / Q000628:therapy*; D015316:Genetic Therapy / Q000379:methods*; D000882:Haplorhini; D016328:NF-kappa B / Q000037:antagonists & inhibitors*; D020319:Oligodeoxyribonucleotides, Antisense; D051381:Rats
D016328:NF-kappa B; D020319:Oligodeoxyribonucleotides, Antisense